1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer. (23rd October 2018) - Colombo, N; Nicoletto, O; Benedetti Panici, P; Tognon, G; Lissoni, A A; Bologna, A; Tomao, F; Fossati, R; Tettamanzi, F; Rulli, E; Galli, F; Alvisi, M F; et al.